ROSEN, A LONGSTANDING LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SCYXBusiness Wire • 11/09/23
SCYNEXIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 11/09/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of SCYNEXIS, Inc. (SCYX) InvestorsBusiness Wire • 11/08/23
SCYX CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against SCYNEXIS, Inc.Business Wire • 11/07/23
SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)GlobeNewsWire • 10/24/23
The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of InvestorsPRNewsWire • 10/06/23
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Scynexis, Inc. (SCYX)Business Wire • 09/29/23
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsBusiness Wire • 09/29/23
SCYNEXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating SCYNEXIS, Inc. on Behalf of Scynexis Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 09/29/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsBusiness Wire • 09/28/23
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substanceGlobeNewsWire • 09/28/23
The Law Offices of Frank R. Cruz Continues Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsBusiness Wire • 09/27/23
Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)Seeking Alpha • 09/26/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsBusiness Wire • 09/25/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsBusiness Wire • 09/25/23
The Law Offices of Frank R. Cruz Announces Investigation of Scynexis, Inc. (SCYX) on Behalf of InvestorsBusiness Wire • 09/25/23
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/23
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco TagliettiGlobeNewsWire • 07/24/23
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in ChinaGlobeNewsWire • 07/20/23
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSKGlobeNewsWire • 06/21/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating SCYNEXIS, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 06/20/23